Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWJ1252 in Functional Dyspepsia (Part 1)
NCT03024086Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mosapride in functional dyspepsia (FD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Gastrointestinal Symptom Score at 4 weeks. Started Dec 2016; status: completed.
02
Drugs
mosapride
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT03024086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024086.